Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: Particular activity against advanced hematologic malignancies

Blood

Volumn 112, Issue 2, 2008, Pages 415-425

  Marks, Reinhard ^a   Potthoff, Karin ^a   Hahn, Joachim ^b   Ihorst, Gabriele ^c   Bertz, Hartmut ^a   Spyridonidis, Alexandras ^a   Holler, Ernst ^b   Finke, Jürgen M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOTOXICITY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CHIMERA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENGRAFTMENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; ALLOTRANSPLANTATION; BLOOD DISEASE; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 47649090155     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-104745     Document Type: Article

References (28)

1. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006;20:1661-1672.
2. Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation tor acute leukemias: "what is the best recipe?" Bone Marrow Transplant. 2005;36:565-574.
3. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
4. Ho AY, Pagliuca A, Kenyon M, et al. Reducedintensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine. busulphan. and alemtuzumab (FBC) conditioning. Blood. 2004;104: 1616-1623.
5. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071-1078.
6. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480-1484.
7. Wong R, Giralt SA, Martin T, et al. Reducedintensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052-3059.
8. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021-2030.
9. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment tor acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006; 24:444-453.
10. Schmid C, Schleuning M, Schwerdtteger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006; 108:1092-1099.
11. Wasch R, Reisser S, Hahn J, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant. 2000;26:243-250.
12. Spyridonidis A, Bertz H, Ihorst G, Grullich C, Finke J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies. Blood. 2005;105:4147-4148.
13. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988; 6:1562-1568.
14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
15. Shulman HM, Sullivan KM, Weiden PL, etal. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
16. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versustumor effects. Blood. 2001;97:3390-3400.
17. Shimoni A, Kroger N, Zabelina T, et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia. 2005;19:7-12.
18. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
19. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234-3241.
20. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97: 631-637.
21. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865-872.
22. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reducedintensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387-9393.
23. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322-328.
24. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201-1207.
25. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AMLHD98-B. Blood. 2006;108: 3280-3288.
26. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304-2312.
27. de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol. 2006;43:107-117.
28. van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5728-5738.